Next Article in Journal
Thoracic, Lumbar, and Sacral Pedicle Screw Placement Using Stryker-Ziehm Virtual Screw Technology and Navigated Stryker Cordless Driver 3: Technical Note
Next Article in Special Issue
Developing Interventional Radiology Anticoagulation Guidelines: Process and Benefits
Previous Article in Journal
Review of the Latest Percutaneous Devices in Critical Limb Ischemia
Previous Article in Special Issue
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Open AccessArticle

Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma

1
Department of Interventional Radiology, Division of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA
2
Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
3
Division of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(4), 83; https://doi.org/10.3390/jcm7040083
Received: 4 April 2018 / Revised: 9 April 2018 / Accepted: 9 April 2018 / Published: 14 April 2018
(This article belongs to the Special Issue Image Guided Interventions and Emerging Technologies)
Predicting outcomes in patients with hepatocellular carcinoma (HCC) who undergo locoregional therapies remains a substantial clinical challenge. The purpose of this study was to investigate pre-procedure diffusion weighted magnetic resonance imaging (DW-MRI) as an imaging biomarker for tumoral response to therapy for patients with HCC undergoing drug eluting embolic (DEE) chemoembolization and radioembolization. A retrospective review of HCC patients who underwent DEE chemoembolization or radioembolization was performed. Of the 58 patients who comprised the study population, 32 underwent DEE chemoembolization and 26 underwent radioembolization. There was no significant difference in median apparent diffusion coefficient (ADC) values across the two treatment groups (1.01 × 10−3 mm2/s, P = 0.25). The immediate objective response (OR) rate was 71% (40/56). Tumors with high ADC values were found to have a higher probability of OR within 90 days (odds ratio 4.4, P = 0.03). Moreover, index lesion specific progression free survival (PFS) was greater for high ADC tumors, independent of conventional predictors of treatment response (hazard ratio 0.44, P = 0.01). Low ADC was associated with poorer PFS (P = 0.02). Pre-procedure ADC < 1.01 × 10−3 mm2/s is an independent predictor of poorer immediate OR and index lesion specific PFS in patients with HCC undergoing DEE chemoembolization or radioembolization. View Full-Text
Keywords: hepatocellular carcinoma; diffusion weighted imaging; chemoembolization hepatocellular carcinoma; diffusion weighted imaging; chemoembolization
Show Figures

Figure 1

MDPI and ACS Style

Niekamp, A.; Abdel-Wahab, R.; Kuban, J.; Odisio, B.C.; Mahvash, A.; Hassan, M.M.; Qayyum, A.; Kaseb, A.; Sheth, R.A. Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma. J. Clin. Med. 2018, 7, 83.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop